Stockscreener 앱 받기
18.76
4.43%
-0.87
전일 마감가:
$19.63
열려 있는:
$19.53
하루 거래량:
405.45K
Relative Volume:
0.99
시가총액:
$534.92M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-8.7256
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
-8.89%
1개월 성능:
-32.05%
6개월 성능:
-39.83%
1년 성능:
-5.54%
1일 변동 폭
$18.74
$19.91
1주일 범위
$18.70
$20.91
52주 변동 폭
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
18.76 | 534.92M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Major Breakthrough: 10,000-Patient Study Proves Castle's Skin Cancer Tests Save Lives - StockTitan
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers - Defense World
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Position Boosted by Truist Financial Corp - Defense World
Leerink Partnrs Weighs in on CSTL Q1 Earnings - Defense World
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $37.00 - Defense World
Castle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst Upgrade - Defense World
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing? - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates - MSN
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences: Strong Growth Potential and Robust Performance Justify Buy Rating - TipRanks
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2024 Earnings Call Transcript - Insider Monkey
Q4 2024 Castle Biosciences Inc Earnings Call - Cbainfo
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Castle Biosciences Reports Strong 2024 Financial Results - TipRanks
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Castle Biosciences Q4 2024 sees strong earnings beat - Investing.com
Castle Biosciences Reports Strong 2024 Financial Performance - TipRanks
How Did Castle Biosciences Transform a $57.5M Loss Into $18.2M Profit? 2024 Results Reveal the Answer - StockTitan
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnin - GuruFocus.com
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings - Yahoo Finance
Castle Biosciences to Participate in Upcoming Investor Conferences - The Bakersfield Californian
When Can You Hear From Castle Biosciences Management? Key March Conference Dates Announced - StockTitan
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewswire
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now - Simply Wall St
Castle Biosciences CFO Frank Stokes sells $214,828 in stock By Investing.com - Investing.com Australia
Castle Biosciences CFO Frank Stokes sells $214,828 in stock - Investing.com India
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High? - MSN
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Castle Biosciences (CSTL) Expected to Announce Earnings on Thursday - Defense World
Castle Biosciences director sells $221,636 in stock - MSN
Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $40.29 - Defense World
Stephens Inc. AR Trims Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock - MSN
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology ConferenceHawaii® - The Bakersfield Californian
Major Clinical Findings: Castle Bio's Breakthrough Melanoma and Skin Cancer Detection Tests Under Spotlight - StockTitan
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in Stock - Armenian Reporter
Castle Biosciences director sells $221,636 in stock By Investing.com - Investing.com Australia
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 - BioSpace
Castle Biosciences Earnings Alert: Key Financial Results Coming Feb 27Here's How to Listen In - StockTitan
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.44%
자본화:
|
볼륨(24시간):